Titan Pharmaceuticals, Inc.  

(Public, NASDAQ:TTNP)   Watch this stock  
Find more results for OTC:TTNP
+0.09 (1.50%)
May 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.96 - 6.18
52 week 2.57 - 10.00
Open 6.02
Vol / Avg. 105,127.00/206,307.00
Mkt cap 120.96M
P/E     -
Div/yield     -
EPS -0.56
Shares 20.06M
Beta 1.93
Inst. own 9%
May 11, 2016
Q1 2016 Titan Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 15, 2016
Q4 2015 Titan Pharmaceuticals Inc Earnings Call
Mar 15, 2016
Q4 2015 Titan Pharmaceuticals Inc Earnings Release
Mar 14, 2016
Titan Pharmaceuticals Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -674.99%
Operating margin - -404.49%
EBITD margin - -383.06%
Return on average assets -65.27% -66.08%
Return on average equity -115.69% -144.59%
Employees 13 -
CDP Score - -


400 Oyster Point Blvd Ste 505
United States - Map
+1-415-2444990 (Phone)
+1-650-2444956 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company developing therapeutics for the treatment of medical disorders. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. Titan's drug candidate, Probuphine, is in Phase III clinical study stage. The Company is also engaged in the development of its ProNeura-Ropinirole product to deliver dopamine agonists for the treatment of Parkinson's disease. The Company has licensed the rights to commercialize Probuphine in the United States and Canada to Braeburn Pharmaceuticals Sprl (Braeburn).

Officers and directors

Marc Rubin M.D. Executive Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Sunil Ramraje Bhonsle President, Director
Age: 65
Bio & Compensation  - Reuters
Joseph A. Akers Independent Director
Age: 69
Bio & Compensation  - Reuters
Victor J. Bauer Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters
Eurelio M. Cavalier Independent Director
Age: 82
Bio & Compensation  - Reuters
M. David David MacFarlane Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
James R. McNab Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters